Article Details

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives “Buy” Rating from Maxim Group

Retrieved on: 2019-05-23 23:22:30

Tags for this article:

Click the tags to see associated articles and topics

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives “Buy” Rating from Maxim Group. View article details on hiswai:

Excerpt

<div><b>Renaissance Technologies</b> LLC increased its holdings in shares of Brainstorm Cell Therapeutics by 16.0% in the 3rd quarter. <b>Renaissance</b> ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up